<DOC>
	<DOCNO>NCT03058744</DOCNO>
	<brief_summary>Suppression Potential Topically Applied IDP-118 Lotion HP Monad Lotion Subjects Moderate Severe Plaque Psoriasis .</brief_summary>
	<brief_title>Topically Applied IDP-118 Lotion HP Monad Lotion Subjects With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>A Phase 1b Open-Label , Randomized Study Evaluating Absorption Systemic Pharmacokinetics HPA Axis Suppression Potential Topically Applied IDP-118 Lotion HP Monad Lotion Subjects Moderate Severe Plaque Psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Halobetasol</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>Male Female race , least 18 year old age ( inclusive ) Freely provide write oral informed consent . Has clinical diagnosis psoriasis Baseline visit Investigator 's Global Assessment Score 3 4 . The face , scalp , axilla , intertriginous area exclude calculation . Has area plaque psoriasis topical treatment involve BSA least 20 % . The willing able avoid prolong exposure treatment area ultraviolet radiation ( natural artificial ) duration study . Key Has spontaneously improve rapidly deteriorate plaque psoriasis postural psoriasis , determine investigator . Presents psoriasis treat prescription medication fail respond present ) . Has history adrenal disease . Presents concurrent skin condition could interfere evaluation treatment area , determine investigator . Is pregnant , nursing , plan pregnancy study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>